Octagam 5gm/50ml Inj, 50ml

Manufacturer OCTAPHARMA USA Active Ingredient Immune Globulin (IV)(i MYUN GLOB yoo lin) Pronunciation OC-tah-gam (as in 'octa' for eight, 'gam' for gamma globulin)
WARNING: There is a chance of blood clots with this drug. The chance is raised in older people and in people with thick blood, heart problems, or a history of blood clots. The chance may also be higher if you must be in a bed or chair for some time, if you take estrogen, or if you use certain catheters. However, blood clots can happen even if you do not have any of these health problems. Call your doctor right away if you have numbness or weakness on 1 side of your body; pain, redness, tenderness, warmth, or swelling in the arms or legs; change in color of an arm or leg; chest pain or pressure; shortness of breath; fast heartbeat; or coughing up blood. Talk with your doctor.Kidney problems have happened with human immune globulin. Sometimes, these problems have been deadly. Kidney problems are more common in people using products that have sucrose. Most immune globulin products do not have sucrose. The chance of these problems may be raised if you have kidney problems, high blood sugar (diabetes), fluid loss (dehydration) or low blood volume, a blood infection, or proteins in the blood that are not normal. The chance may be raised if you are 65 or older, or if you take other drugs that may harm the kidneys. Talk with your doctor if you have questions about this information or about if your product has sucrose.You will need to be sure that you are not dehydrated before getting this drug. Check with your doctor to see if you need to drink extra fluids before getting this drug. @ COMMON USES: It is used to help prevent infections or make infections less severe in people with a weak immune system.It is used to treat immune thrombocytopenia (ITP).It is used treat chronic inflammatory demyelinating polyneuropathy (CIDP).It is used to treat Kawasaki disease.It is used to treat a certain muscle problem caused by inflammation (dermatomyositis).It may be given to you for other reasons. Talk with the doctor.
đŸˇī¸
Drug Class
Immunomodulator; Blood product derivative
đŸ§Ŧ
Pharmacologic Class
Immune Globulin (Human)
🤰
Pregnancy Category
Category C
✅
FDA Approved
Jul 2010
âš–ī¸
DEA Schedule
Not Controlled

Overview

â„šī¸

What is this medicine?

Octagam is a medicine made from human blood plasma that contains antibodies (proteins that fight infections). It is given by infusion into a vein to help people with certain immune system problems or conditions where the body's immune system attacks its own cells.
📋

How to Use This Medicine

To use this medication correctly, follow your doctor's instructions and carefully read all accompanying information. Take this medication exactly as directed, and adhere to all guidelines provided. This drug is administered via infusion into a vein over a specified period of time.

For proper storage and disposal of this medication, consult with your doctor, nurse, or pharmacist to determine the best approach if you need to store it at home.

If you miss a dose, contact your doctor immediately to receive guidance on the appropriate course of action.
💡

Lifestyle & Tips

  • Stay well-hydrated before, during, and after your infusion to help prevent side effects, especially kidney problems.
  • Report any unusual symptoms immediately to your healthcare provider.
  • Avoid live virus vaccines for several months after receiving Octagam, as it may make the vaccine less effective. Discuss your vaccination schedule with your doctor.

Dosing & Administration

đŸ‘¨â€âš•ī¸

Adult Dosing

Standard Dose: Highly variable by indication. Examples: Primary Humoral Immunodeficiency (PI): 300-600 mg/kg every 3-4 weeks. Idiopathic Thrombocytopenic Purpura (ITP): 1 g/kg daily for 1-2 days or 400 mg/kg daily for 5 days. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Loading dose 2 g/kg over 2-5 days, then maintenance 1 g/kg over 1-2 days every 3 weeks.
Dose Range: 300 - 2000 mg

Condition-Specific Dosing:

Primary Humoral Immunodeficiency (PI): 300-600 mg/kg every 3-4 weeks
Idiopathic Thrombocytopenic Purpura (ITP): 1 g/kg daily for 1-2 days or 400 mg/kg daily for 5 days
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Loading dose 2 g/kg over 2-5 days, then maintenance 1 g/kg over 1-2 days every 3 weeks
đŸ‘ļ

Pediatric Dosing

Neonatal: Not established for all indications; use with caution and specific guidance.
Infant: Dosing similar to adult for approved indications (e.g., PI, ITP) based on weight, but specific pediatric guidelines should be followed.
Child: Dosing similar to adult for approved indications (e.g., PI, ITP) based on weight, but specific pediatric guidelines should be followed.
Adolescent: Dosing similar to adult for approved indications (e.g., PI, ITP) based on weight, but specific pediatric guidelines should be followed.
âš•ī¸

Dose Adjustments

Renal Impairment:

Mild: Use with caution; ensure adequate hydration. Octagam is sucrose-free, reducing renal risk compared to sucrose-containing IVIGs.
Moderate: Use with caution; ensure adequate hydration. Monitor renal function closely. Consider lower infusion rates.
Severe: Use with extreme caution; monitor renal function closely. Consider lower infusion rates and doses if possible. Risk of acute renal failure.
Dialysis: Not specifically studied; generally, IVIG is not significantly removed by dialysis. Use with caution and monitor fluid status and renal function.

Hepatic Impairment:

Mild: No specific dose adjustment required.
Moderate: No specific dose adjustment required.
Severe: No specific dose adjustment required.

Pharmacology

đŸ”Ŧ

Mechanism of Action

Immune Globulin Intravenous (Human) provides a broad spectrum of IgG antibodies against various infectious agents and toxins. Its mechanism of action in immunomodulatory conditions (e.g., ITP, CIDP) is complex and not fully elucidated, involving: Fc-receptor blockade on macrophages, modulation of cytokine production, anti-idiotypic antibodies, complement modulation, and regulation of B and T cell activity.
📊

Pharmacokinetics

Absorption:

Bioavailability: 100%
Tmax: End of infusion
FoodEffect: Not applicable (IV administration)

Distribution:

Vd: Approximately 0.07 L/kg (initial distribution primarily intravascular, then extravascular)
ProteinBinding: >95% (as IgG)
CnssPenetration: Limited (intact IgG molecules generally do not cross the blood-brain barrier significantly, but can be used in neurological conditions due to peripheral effects or minor penetration)

Elimination:

HalfLife: Approximately 21-30 days (variable among individuals and indications)
Clearance: Variable, depends on individual IgG catabolism rate.
ExcretionRoute: Primarily intracellular catabolism; minimal renal excretion of intact IgG.
Unchanged: Not applicable (protein catabolism)
âąī¸

Pharmacodynamics

OnsetOfAction: Immediate (antibody levels); clinical effect varies by indication (e.g., ITP platelet count increase within days, CIDP symptom improvement over weeks).
PeakEffect: Variable by indication and dose (e.g., ITP platelet count peak within 2-7 days; PI IgG trough levels before next infusion).
DurationOfAction: Variable, typically corresponds to half-life of IgG (weeks to months), but clinical effect may be shorter depending on the condition.

Safety & Warnings

âš ī¸

BLACK BOX WARNING

Thrombosis may occur with immune globulin products, including Octagam. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, and high viscosity. For patients at risk of thrombosis, administer Octagam at the minimum dose and infusion rate practicable. Ensure adequate hydration prior to administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
âš ī¸

Side Effects

Urgent Side Effects: Seek Medical Help Right Away

Although rare, some people may experience severe and potentially life-threatening side effects while taking this medication. If you notice any of the following symptoms, contact your doctor or seek medical attention immediately:

Signs of an allergic reaction, such as:
+ Rash
+ Hives
+ Itching
+ Red, swollen, blistered, or peeling skin with or without fever
+ Wheezing
+ Tightness in the chest or throat
+ Trouble breathing, swallowing, or talking
+ Unusual hoarseness
+ Swelling of the mouth, face, lips, tongue, or throat
Signs of kidney problems, including:
+ Inability to pass urine
+ Changes in urine output
+ Blood in the urine
+ Sudden weight gain
Signs of high or low blood pressure, such as:
+ Severe headache or dizziness
+ Passing out
+ Changes in eyesight
Fever, chills, or sore throat
Unexplained bruising or bleeding
Feeling extremely tired or weak
Blue or gray discoloration of the skin, lips, nail beds, fingers, or toes
Seizures
Bloating
Confusion
Swelling
Abnormal heartbeat
Mood changes
Muscle or joint pain
Changes in speech or eyesight
Shakiness
Excessive sweating
Severe stomach pain
Dark urine or yellow skin and eyes

Severe Lung Problems and Aseptic Meningitis

This medication can cause severe lung problems, which can be life-threatening. If you experience any of the following symptoms, contact your doctor right away:
Trouble breathing
Shortness of breath
New or worsening cough

Additionally, this medication may increase the risk of aseptic meningitis, a severe brain problem. If you experience any of the following symptoms, contact your doctor immediately:
Headache
Fever
Chills
Severe nausea or vomiting
Stiff neck
Rash
Sensitivity to light
Feeling sleepy or confused

Other Important Side Effects

Some patients, especially those receiving immune globulin therapy for the first time or who have not had it within the past 8 weeks, may be at risk for certain side effects, including:
Fever
Chills
Nausea
Vomiting

This may also occur in people who switch brands of immune globulin. If you experience any of these side effects, contact your doctor right away.

Dehydration and Low Sodium Levels

This medication can cause dehydration and low sodium levels when given intravenously. If you experience any of the following symptoms, contact your doctor immediately:
Signs of dehydration, such as:
+ Dry skin, mouth, or eyes
+ Thirst
+ Fast heartbeat
+ Dizziness
+ Fast breathing
+ Confusion
Signs of low sodium levels, such as:
+ Headache
+ Trouble focusing
+ Memory problems
+ Feeling confused
+ Weakness
+ Seizures
+ Changes in balance

Other Side Effects

Most people do not experience significant side effects, but some may occur. If you experience any of the following side effects or any other symptoms that bother you or do not go away, contact your doctor:
Irritation at the injection site
Dizziness, tiredness, or weakness
Headache
Upset stomach or vomiting
Stomach pain or diarrhea
Back pain
Muscle spasm
Signs of a common cold
Flushing
Cramps

Reporting Side Effects

If you have questions about side effects or want to report any side effects, contact your doctor. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.
🚨

Seek Immediate Medical Attention If You Experience:

  • Severe headache, especially with neck stiffness or sensitivity to light (signs of aseptic meningitis)
  • Sudden chest pain, shortness of breath, or pain/swelling in an arm or leg (signs of blood clot)
  • Decreased urination, swelling in legs or feet (signs of kidney problems)
  • Severe allergic reaction symptoms: difficulty breathing, hives, swelling of face/lips/tongue/throat, dizziness, rapid heartbeat
  • Fever, chills, nausea, vomiting, or muscle aches during or shortly after infusion
📋

Before Using This Medicine

Before Taking This Medication: Important Information to Share with Your Doctor

It is essential to inform your doctor about the following conditions to ensure safe treatment:

Any allergies you have, including allergies to this medication, its components, or other substances. Be sure to describe the symptoms you experienced.
If you have IgA deficiency or hyperprolinemia (elevated proline levels in your blood).
If you have excess fluid in your body or have been advised to monitor your fluid intake.
If you are unable to break down fructose, consult with your doctor, as some products contain sorbitol.

Special Considerations for Children:

* If your child is an infant or baby, and it is unclear whether they can break down sucrose or fructose, do not administer this medication.

This list is not exhaustive, and it is crucial to discuss all your medications (prescription, over-the-counter, natural products, and vitamins) and health conditions with your doctor and pharmacist. Verify that it is safe to take this medication with your existing treatments and health issues. Never start, stop, or adjust the dosage of any medication without consulting your doctor.
âš ī¸

Precautions & Cautions

It is essential to inform all your healthcare providers, including doctors, nurses, pharmacists, and dentists, that you are taking this medication. If you have a latex allergy, be sure to discuss this with your doctor.

Before receiving any vaccinations, consult with your doctor, as certain vaccines may not be effective or may increase the risk of infection when taken with this drug.

Regular blood tests and other laboratory evaluations should be performed as directed by your doctor. Additionally, inform all your healthcare providers and laboratory personnel that you are taking this medication, as it may affect the results of certain lab tests.

If you have a weakened immune system and have been exposed to measles, consult with your doctor. It is also important to note that this medication is derived from human plasma and may potentially contain viruses that can cause disease. Although the product is thoroughly screened, tested, and treated to minimize the risk of infection, discuss this with your doctor.

If you are following a low-sodium or sodium-free diet, consult with your doctor, as some formulations of this medication may contain sodium. Furthermore, if you have diabetes (high blood sugar), discuss with your doctor which glucose tests are most suitable for you to use.

When taking this medication, individuals 65 years or older should exercise caution, as they may be more susceptible to side effects.

If you are pregnant, plan to become pregnant, or are breastfeeding, inform your doctor, as it is crucial to discuss the potential benefits and risks of this medication to both you and your baby.
🆘

Overdose Information

Overdose Symptoms:

  • Fluid overload (e.g., shortness of breath, swelling)
  • Increased blood viscosity
  • Acute renal dysfunction
  • Thrombotic events

What to Do:

Discontinue infusion immediately. Provide supportive care, including diuresis for fluid overload. Monitor vital signs, renal function, and coagulation parameters. Call 1-800-222-1222 (Poison Control) or seek emergency medical attention.

Drug Interactions

🔴

Major Interactions

  • Live virus vaccines (e.g., measles, mumps, rubella, varicella): May interfere with the immune response to these vaccines. Defer vaccination for at least 3 months after IVIG administration. For measles, defer for up to 1 year depending on IVIG dose.
  • Loop diuretics (e.g., furosemide): Increased risk of acute renal failure when co-administered with IVIG, especially in patients with pre-existing renal impairment or risk factors.
🟡

Moderate Interactions

  • Nephrotoxic drugs: Increased risk of renal dysfunction when co-administered with other nephrotoxic agents (e.g., aminoglycosides, NSAIDs, contrast media).
  • Anticoagulants/Antiplatelets: Theoretical increased risk of thrombosis, though not a direct interaction, but rather a shared risk factor for thrombotic events.

Monitoring

đŸ”Ŧ

Baseline Monitoring

Renal function (BUN, serum creatinine)

Rationale: To assess baseline renal status and identify patients at risk for acute renal dysfunction.

Timing: Prior to initiation of therapy.

Hydration status

Rationale: To ensure adequate hydration, which is crucial for preventing renal complications.

Timing: Prior to and during infusion.

Serum IgA levels

Rationale: To screen for IgA deficiency, as patients with severe IgA deficiency may develop anti-IgA antibodies and be at risk for anaphylactic reactions.

Timing: Prior to first infusion.

Complete Blood Count (CBC) with differential

Rationale: To assess baseline hematologic status, especially for ITP patients.

Timing: Prior to initiation of therapy.

📊

Routine Monitoring

Vital signs (blood pressure, heart rate, temperature)

Frequency: Before infusion, 15-30 minutes into infusion, and periodically thereafter, and at the end of infusion.

Target: Within normal limits for patient.

Action Threshold: Significant changes (e.g., hypotension, tachycardia, fever) warrant slowing or stopping infusion and assessing for adverse reactions.

Urine output

Frequency: During and after infusion, especially in at-risk patients.

Target: Adequate for hydration status.

Action Threshold: Oliguria or anuria may indicate acute renal dysfunction.

Serum creatinine

Frequency: Before each infusion, or more frequently in patients at risk for renal dysfunction.

Target: Within baseline limits.

Action Threshold: Significant increase (e.g., >0.5 mg/dL from baseline) warrants investigation and potential dose/rate adjustment.

Signs/symptoms of thrombosis

Frequency: Throughout therapy and for several days post-infusion.

Target: Absence of symptoms.

Action Threshold: New onset pain, swelling, discoloration of an extremity, shortness of breath, chest pain, neurological deficits.

đŸ‘ī¸

Symptom Monitoring

  • Headache
  • Fever
  • Chills
  • Nausea
  • Vomiting
  • Rash
  • Hives
  • Dyspnea
  • Chest tightness
  • Back pain
  • Flushing
  • Signs of allergic reaction (e.g., anaphylaxis)
  • Signs of thrombosis (e.g., pain/swelling in limb, shortness of breath, chest pain, neurological changes)
  • Signs of acute renal dysfunction (e.g., decreased urine output, swelling)
  • Signs of aseptic meningitis (e.g., severe headache, nuchal rigidity, photophobia, fever, nausea, vomiting)

Special Patient Groups

🤰

Pregnancy

Category C. Animal reproduction studies have not been conducted. However, immune globulins are known to cross the placental barrier, particularly in the third trimester. Octagam should be given to a pregnant woman only if clearly needed. Clinical experience with IVIG in pregnant women suggests no adverse effects on the course of pregnancy, fetus, or neonate.

Trimester-Specific Risks:

First Trimester: Limited data, but generally considered low risk as IgG transfer is minimal.
Second Trimester: Limited data, but generally considered low risk.
Third Trimester: Significant placental transfer of IgG occurs, potentially providing passive immunity to the fetus. No known specific risks to fetus from IVIG itself, but underlying maternal condition and potential adverse reactions to IVIG should be considered.
🤱

Lactation

L2 (Safer). Immune globulins are naturally present in human milk and are transferred to the infant. Oral absorption of intact IgG by infants is minimal. No adverse effects on the breastfed infant are expected. Octagam can be used during lactation if clinically indicated.

Infant Risk: Low risk.
đŸ‘ļ

Pediatric Use

Safety and efficacy have been established in pediatric patients for certain indications (e.g., PI, ITP). Dosing is weight-based. Caution is advised in neonates and infants due to potential for fluid overload and renal immaturity. Infusion rates may need to be slower.

👴

Geriatric Use

Use with caution in elderly patients, especially those with pre-existing renal impairment, diabetes, or cardiovascular disease, due to increased risk of acute renal dysfunction and thrombotic events. Ensure adequate hydration and use the minimum dose and infusion rate practicable.

Clinical Information

💎

Clinical Pearls

  • Always ensure adequate hydration before, during, and after IVIG infusion to minimize the risk of renal complications.
  • Infuse slowly initially, especially for first-time infusions or in patients at high risk for adverse reactions. The infusion rate can be gradually increased if tolerated.
  • Pre-medication (e.g., acetaminophen, antihistamines, corticosteroids) may be considered for patients with a history of infusion-related reactions.
  • Monitor for signs of aseptic meningitis (severe headache, neck stiffness, photophobia) which can occur hours to days after infusion.
  • Be vigilant for signs of thrombosis, particularly in patients with risk factors. Consider assessing blood viscosity in high-risk patients.
  • Octagam is sucrose-free, which is an advantage for renal safety compared to some other IVIG products, but renal monitoring is still crucial.
🔄

Alternative Therapies

  • Other Immune Globulin Intravenous (IVIG) products (e.g., Gammagard S/D, Gamunex-C, Privigen, Flebogamma DIF)
  • Subcutaneous Immune Globulin (SCIG) products (e.g., Hizentra, Cuvitru, Xembify, Gamunex-C/Gammagard S/D for subcutaneous use) for primary immunodeficiency.
  • For ITP: Corticosteroids, anti-D immunoglobulin, thrombopoietin receptor agonists (e.g., eltrombopag, romiplostim), splenectomy.
  • For CIDP: Corticosteroids, plasma exchange (PLEX).
💰

Cost & Coverage

Average Cost: Highly variable, typically thousands to tens of thousands of dollars per infusion depending on dose and frequency. per 50ml vial (5gm)
Insurance Coverage: Specialty Tier / Tier 4 (requires prior authorization and medical necessity documentation)
📚

General Drug Facts

If your symptoms or health problems do not improve or worsen over time, it is essential to contact your doctor for further evaluation and guidance. To ensure safe use, never share your prescription medications with others, and do not take medications prescribed to someone else. Store all medications in a secure location, out of reach of children and pets, to prevent accidental ingestion. Properly dispose of unused or expired medications by checking with your pharmacist for guidance on the best disposal method. Unless instructed to do so, avoid flushing medications down the toilet or pouring them down the drain, as this can harm the environment. Many communities have drug take-back programs that provide a safe and responsible way to dispose of medications. Some medications may have additional patient information leaflets available; consult with your pharmacist if you have questions. If you have concerns or questions about your medication, discuss them with your doctor, nurse, pharmacist, or other healthcare provider. In the event of a suspected overdose, immediately call your local poison control center or seek emergency medical attention. Be prepared to provide information about the medication taken, the amount, and the time it was taken to ensure prompt and effective treatment.